Delivery Order SPE2DB24D2105-SPE2DB25FAQGR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $24,367.44 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count package) on August 27, 2025, with an ultimate completion date of September 18, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in that...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 125 mg capsules (21-count packaging). This is a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. The order is scheduled for completion by October 9, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,236.16 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg tablets (7-count units) on August 25, 2025, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $40,612.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count packaging) with an ultimate completion date of September 30, 2025. This competitive award, issued on September 9, 2025, carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 100 mg, a prescription medication used in cancer treatment. The contract, awarded on August 8, 2025, with an ultimate completion date of August 29, 2025, carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a $40,609.48 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 100 mg capsules (quantity 21s), with an ultimate completion date of October 2, 2025. This non-set-aside contract is to be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count package) under a firm fixed price contract. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQGRDelivery Order
The Defense Logistics Agency (DLA) awarded a $16,244.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 21 capsules of Ibrance 100 mg on September 25, 2025, with an ultimate completion date of October 17, 2025. This award carries no set-aside designation and represents a competitively awarded contract. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime contractor supporting the Defense Health Agency and other federal healthcare systems, AmerisourceBergen leverages this comprehensive global pharmaceutical vehicle to supply critical medications across multiple therapeutic domains to support military healthcare programs worldwide. Ibrance, a brand-name oncology medication, represents part of the company's extensive portfolio of specialty pharmaceuticals and medical supplies delivered through firm fixed-price delivery orders under the broader IDC framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 9/25/25 |